ISG Announces 2025 ISG Paragon Awards™ ANZ Winners
A total of 45 nominations were submitted for the ANZ program, which started in 2010 and is now in its fifteenth year. Winners were selected by an independent judge and announced at a gala awards dinner on Thursday, May 8, 2025, at the Grand Hyatt Melbourne.
The winners of the 2025 ANZ awards are:
Excellence: Outstanding delivery by a service provider
Winner: Genpact Australia Pty Ltd with AMP Limited
Innovation: Imagination and entrepreneurial spirit in helping organizations future-proof their businesses and better serve clients
Winner: Unisys Australia Pty Limited with NSW Department of Communities and Justice
Transformation: The successful transformation of an organization or key business function
Winner: PwC Australia with AMP Limited
Sustainability: Exceptional implementations of digital sustainability strategies and initiatives
Winner: HCL Technologies Limited with WaterNSW
AI Pacesetter: Substantial business impact through the adoption of AI
Winner: Tata Consultancy Services Limited with Foxtel Management Pty Ltd
Partnership of the Year: Partnerships that demonstrate seamless collaboration, leverage each other's strengths and adapt together to achieve shared objectives
Winner: Wipro Technologies Australia Pty Ltd with AusNet Services and Palo Alto Networks
"ISG research finds enterprises in Australia are investing in digital transformation to deliver rapid, measurable results and are turning to provider partnerships for support with AI-centric initiatives,' said Michael Gale, partner and regional leader, ISG Asia Pacific. "Congratulations to the 2025 winners of the ISG Paragon Awards ANZ. Their commitment to delivering impactful business results is reflected in each of their winning partnerships.'
The 2025 ISG ANZ Paragon Awards celebrate the evolution of the sourcing industry through the application of new sourcing approaches, AI and digital technology. Full details are available here.
About ISG
ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Evercore adds Affirm to its Tactical Underperform list
-- Evercore ISI added Affirm Holdings (NASDAQ:AFRM) to its Tactical Underperform (TAP) list, citing stretched valuations and the stock's sharp rally heading into next week's earnings. Affirm shares have surged 115% since April and 18% since the start of August, making it the best performer year-to-date under Evercore's coverage. Analysts said the run-up leaves 'the risk/reward less favorable heading into next week's print than it was a few weeks ago.' The broker highlighted that Affirm is trading near its recent peak valuation of high-20s next twelve months (NTM) EV/EBITDA, while management's traditionally cautious stance limits the likelihood of guidance exceeding consensus estimates. Still, Evercore maintained its Outperform rating on the stock, describing the TAP call as tactical rather than a change in its longer-term view. 'We still believe AFRM has the best risk platform in the space and will benefit over the longer-term from penetration in new verticals and geographies as well as product expansion,' the analysts led by Adam Frisch wrote. Investors are awaiting Affirm's fiscal fourth-quarter earnings on Aug. 28, when management will outline fiscal 2026 guidance. Evercore expects guidance to be broadly in line with consensus, with gross merchandise volume (GMV) seen growing 27% ex-Walmart and revenue less transaction costs (RLTC) margin at 3.9%. The firm noted risks tied to potential GMV declines at Walmart (NYSE:WMT), which accounts for about 5% of Affirm's volume, after competitor Klarna expanded its OnePay offering. Analysts also pointed to a margin dynamic. Notably, lower Walmart volumes could prove accretive given the partnership's lower economics, though this might be offset by the continued growth in 0% annual percentage rate (APR) loans. Over the past four quarters, Affirm has averaged a Revenue Less Transaction (JO:NTUJ) Costs (RLTC) margin of 4.1%, above management's 3-4% target. 'We expect a 3.9% RLTC margin for FY26 (down 14bps YoY and in line with consensus) but note that could prove a little conservative with continued execution,' analysts said. Related articles Evercore adds Affirm to its Tactical Underperform list After soaring 149%, this stock is back in our AI's favor - & already +25% in July 7 Undervalued Stocks on the Rise With 50%+ Upside Potential Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
8 minutes ago
- Yahoo
What Makes Mama's Creations (MAMA) a Compelling Investment?
Immersion Investment Partners, an investment management company, released its second-quarter 2025 investor letter. A copy of the same can be downloaded here. The fund gained 28.13% in the second quarter, compared to an 8.50% increase for the Russell 2000 Index and a 15.51% increase for the Russell Microcap Index. The firm focuses on the company fundamentals, not on quarterly stock price performance. The firm invested over 80% of net asset value in the top five names. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its second-quarter 2025 investor letter, Immersion Investment Partners highlighted stocks such as Mama's Creations, Inc. (NASDAQ:MAMA). Mama's Creations, Inc. (NASDAQ:MAMA) manufactures and markets fresh deli-prepared foods. The one-month return of Mama's Creations, Inc. (NASDAQ:MAMA) was -11.30%, and its shares lost 0.97% of their value over the last 52 weeks. On August 18, 2025, Mama's Creations, Inc. (NASDAQ:MAMA) stock closed at $8.16 per share, with a market capitalization of $306.903 million. Immersion Investment Partners stated the following regarding Mama's Creations, Inc. (NASDAQ:MAMA) in its second quarter 2025 investor letter: "Mama's Creations, Inc. (NASDAQ:MAMA): Occasionally you run across an executive who is so outlandishly passionate about their job and the brand they represent, you can't help but take notice. We first met Adam Michaels (CEO of MAMA) more than a year ago at an investor conference. Clad in mulberry shoes and sport coat, the exact brand colors of MAMA, he told us how he would take what was historically a subscale meatball manufacturer in suburban New Jersey and make it into one of the largest prepared foods and deli brands in the world. Frankly, we thought he had too many screws loose. Nonetheless, we were intrigued by the business and the category. Fresh and prepared foods in grocery stores has been a growing category, catalyzed by consumer demand for healthier, fast, and affordable food options. Grocery stores have been increasingly dedicating more food space to the category. Today, it is one of only a couple of categories that are seeing volume growth. Mama's Creations, Inc. (NASDAQ:MAMA) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 7 hedge fund portfolios held Mama's Creations, Inc. (NASDAQ:MAMA) at the end of the first quarter, which was 8 in the previous quarter. Mama's Creations, Inc.'s (NASDAQ:MAMA) fiscal Q1 2026 revenue grew approximately 18% year over year, to a record $35.3 million. While we acknowledge the potential of Mama's Creations, Inc. (NASDAQ:MAMA) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
8 minutes ago
- Yahoo
Does LifeCore (LFCR) Have a High Expected Value?
Greenhaven Road Capital, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. A copy of the letter can be downloaded here. In the second quarter, the fund returned approximately +14% net of fees and expenses, bringing the YTD returns to under +1%. YTD, the Russell 2000 has returned -1.8%. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its second-quarter 2025 investor letter, Greenhaven Road Capital highlighted stocks such as Lifecore Biomedical, Inc. (NASDAQ:LFCR). Lifecore Biomedical, Inc. (NASDAQ:LFCR) is an integrated contract development and manufacturing organization. The one-month return of Lifecore Biomedical, Inc. (NASDAQ:LFCR) was -0.54%, and its shares gained 30.05% of their value over the last 52 weeks. On August 18, 2025, Lifecore Biomedical, Inc. (NASDAQ:LFCR) stock closed at $7.40 per share, with a market capitalization of $276.818 million. Greenhaven Road Capital stated the following regarding Lifecore Biomedical, Inc. (NASDAQ:LFCR) in its second quarter 2025 investor letter: "Another holding that I believe has a high expected value is Lifecore Biomedical, Inc. (NASDAQ:LFCR), which I have written about extensively. Here is a link to a recent presentation (link) I did for the investing platform SumZero. Kyle and I visited the manufacturing facility in Minnesota during the quarter and spent time with management and the business development team. As a reminder, LifeCore is a contract drug manufacturer which has recently added significant manufacturing capacity. They are operating at approximately 20% of their capacity with 15% EBITDA margins. A village pharmacist fulfilling a patient's medication prescription in a rural area. Lifecore Biomedical, Inc. (NASDAQ:LFCR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 12 hedge fund portfolios held Lifecore Biomedical, Inc. (NASDAQ:LFCR) at the end of the first quarter compared to 10 in the previous quarter. While we acknowledge the potential of Lifecore Biomedical, Inc. (NASDAQ:LFCR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Lifecore Biomedical, Inc. (NASDAQ:LFCR) and shared Laughing Water Capital's views on the company. Greenhaven Road Capital increased its stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR) in the previous quarter to nearly 10%. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
